Printed from https://ideas.repec.org/s/spr/aphecp2.html
Content
September 2022, Volume 20, Issue 5
- 743-755 Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
by Jia Liu & Xiaoning He & Jing Wu - 757-768 Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
by Daniel Tobias Michaeli & Mackenzie Mills & Panos Kanavos - 769-779 Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia
by Sameera Senanayake & Helen Healy & Steven M. McPhail & Keshwar Baboolal & Sanjeewa Kularatna - 781-782 Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
by Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Mauskopf & C. Daniel Mullins & Stavros Petrou & Raoh-Fang Pwu & Sophie Staniszewska
July 2022, Volume 20, Issue 4
- 453-455 Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?
by Livio Garattini & Bruno Finazzi - 457-465 Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines
by Jamison Pike & Andrew J. Leidner & Harrell Chesson & Charles Stoecker & Scott D. Grosse - 467-477 Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version
by Eun-Young Bae & Jihyung Hong & SeungJin Bae & Seokyung Hahn & Hyonggin An & Eun-joo Hwang & Seung-min Lee & Tae-jin Lee - 479-486 Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy
by Nadine T. Hillock & Tracy L. Merlin & John Turnidge & Jonathan Karnon - 487-499 A Case Study on Reviewing Specialist Services Commissioning in Wales: TAVI for Severe Aortic Stenosis
by Edyta Ryczek & Susan C. Peirce & Laura Knight & Andrew Cleves & Andrew Champion & Iolo Doull & Sian Lewis - 501-524 Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options
by Rositsa Koleva-Kolarova & James Buchanan & Heleen Vellekoop & Simone Huygens & Matthijs Versteegh & Maureen Rutten-van Mölken & László Szilberhorn & Tamás Zelei & Balázs Nagy & Sarah Wordsworth & Apostolos Tsiachristas - 525-541 What Policy Approaches Were Effective in Reducing Catastrophic Health Expenditure? A Systematic Review of Studies from Multiple Countries
by HyunWoo Jung & Kwang-Soo Lee - 543-555 Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
by Sara Stafford & Peter G. Bech & Adam Fridhammar & Nino Miresashvili & Andreas Nilsson & Michael Willis & Aiden Liu - 557-572 How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15
by Stephen Martin & Karl Claxton & James Lomas & Francesco Longo - 573-585 Population Norms for SF-6Dv2 and EQ-5D-5L in China
by Shitong Xie & Jing Wu & Feng Xie - 587-596 Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand
by Piyameth Dilokthornsakul & Ratree Sawangjit & Pisit Tangkijvanich & Maneerat Chayanupatkul & Tawesak Tanwandee & Wattana Sukeepaisarnjaroen & Pajaree Sriuttha & Unchalee Permsuwan - 597-607 Preferred Attributes of Care Pathways for Obstructive Sleep Apnoea from the Perspective of Diagnosed Patients and High-Risk Individuals: A Discrete Choice Experiment
by Andrea N. Natsky & Andrew Vakulin & Ching Li Chai-Coetzer & R. Doug McEvoy & Robert J. Adams & Billingsley Kaambwa - 609-621 Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women
by Nidhi Gupta & Dharna Gupta & Jyoti Dixit & Nikita Mehra & Ashish Singh & Manjunath Nookala Krishnamurthy & Gaurav Jyani & Kavitha Rajsekhar & Jayachandran Perumal Kalaiyarasi & Partha Sarathi Roy & Prabhat Singh Malik & Anisha Mathew & Pankaj Malhotra & Sudeep Gupta & Lalit Kumar & Amal Kataki & Shankar Prinja - 623-623 Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
by Sara Stafford & Peter G. Bech & Adam Fridhammar & Nino Miresashvili & Andreas Nilsson & Michael Willis & Aiden Liu
May 2022, Volume 20, Issue 3
- 287-290 How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
by Charalabos-Markos Dintsios & Nadja Chernyak - 291-303 Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?
by Sándor Kovács & Bertalan Németh & Dalma Erdősi & Valentin Brodszky & Imre Boncz & Zoltán Kaló & Antal Zemplényi - 305-313 Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance
by Ruth Louise Poole & Megan Dale & Helen Morgan & Tosin Oladapo & Rebecca Brookfield & Rhys Morris - 315-335 A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa
by Mouaddh Abdulmalik Nagi & Pramitha Esha Nirmala Dewi & Montarat Thavorncharoensap & Sermsiri Sangroongruangsri - 337-349 Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries
by Laura Vallejo-Torres & Borja García-Lorenzo & Laura Catherine Edney & Niek Stadhouders & Ijeoma Edoka & Iván Castilla-Rodríguez & Lidia García-Pérez & Renata Linertová & Cristina Valcárcel-Nazco & Jonathan Karnon - 351-370 Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review
by Jiayu Shi & Kenan Fan & Lei Yan & Zijuan Fan & Fei Li & Guishan Wang & Haifeng Liu & Peidong Liu & Hongmei Yu & Jiao Jiao Li & Bin Wang - 371-381 Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India
by V. Srinivasan & David E. Bloom & Alex Khoury - 383-393 Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents
by Mimmi Åström & Ola Rolfson & Kristina Burström - 395-404 Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries
by Siyu Ma & Tara A. Lavelle & Daniel A. Ollendorf & Pei-Jung Lin - 405-416 How Did the Affordable Care Act Affect Risky Health Behaviors?
by Cagdas Agirdas - 417-429 Scope Issue in Contingent Valuation Studies of the COVID-19 Vaccine: The Case of China
by Jianhong Xiao & Yihui Wu & Min Wang & Zegang Ma - 431-445 Cost-effectiveness Analysis of the Dental RECUR Pragmatic Randomized Controlled Trial: Evaluating a Goal-oriented Talking Intervention to Prevent Reoccurrence of Dental Caries in Children
by Ezeofor Victory & Edwards T. Rhiannon & Burnside Girvan & Adair Pauline & Pine M. Cynthia - 447-449 Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?
by Howard Thom - 451-451 Correction to: Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?
by Howard Thom
March 2022, Volume 20, Issue 2
- 145-147 Integrated Care in Europe: Time to Get it Together?
by Livio Garattini & Marco Badinella Martini & Alessandro Nobili - 149-158 From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R
by Yiqiao Xin & Ewan Gray & Jose Antonio Robles-Zurita & Houra Haghpanahan & Robert Heggie & Ciaran Kohli-Lynch & Andrew Briggs & David A. McAllister & Kenny D. Lawson & Jim Lewsey - 159-169 Episcissors-60 for Mediolateral Episiotomy: Evaluation of Clinical and Economic Evidence to Inform NICE Medical Technologies Guidance
by Susan O’Connell & Megan Dale & Helen Morgan & Bernice Dillon & Andrew Cleves & Rhys Morris & Grace Carolan-Rees - 171-183 Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations
by Paul G. Carty & Christopher G. Fawsitt & Paddy Gillespie & Patricia Harrington & Michelle O’Neill & Susan M. Smith & Conor Teljeur & Mairin Ryan - 185-198 The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations
by Siyuan Liu & Paul J. Veugelers & Chunhao Liu & Arto Ohinmaa - 199-212 The Effect of Price Changes and Teaspoon Labelling on Intention to Purchase Sugar-Sweetened Beverages: A Discrete Choice Experiment
by Vinh Vo & K.-H. Nguyen & J. A. Whitty & Tracy A. Comans - 213-221 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
by Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Mauskopf & C. Daniel Mullins & Stavros Petrou & Raoh-Fang Pwu & Sophie Staniszewska - 223-233 The Effects of School Closures on COVID-19: A Cross-Country Panel Analysis
by Vincenzo Alfano - 235-241 Are Medical Devices Cost-Effective?
by James D. Chambers & Madison C. Silver & Flora C. Berklein & Joshua T. Cohen & Peter J. Neumann - 243-253 Effect of Competition on Generic Drug Prices
by Nguyen Xuan Nguyen & Steven H. Sheingold & Wafa Tarazi & Arielle Bosworth - 255-267 Willingness to Pay for National Health Insurance: A Contingent Valuation Study Among Patients Visiting Public Hospitals in Melaka, Malaysia
by Robin Tiow Heng Tan & Siti Zaleha Abdul Rasid & Wan Khairuzzaman Wan Ismail & Janiza Tobechan & Edwin Tiow Yong Tan & Alia Natasha Yusof & Jia Hui Low - 269-282 Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study
by Caroline S. Clarke & Larisa Duffy & Glyn Lewis & Nick Freemantle & Simon Gilbody & Tony Kendrick & David Kessler & Michael King & Paul Lanham & Derelie Mangin & Michael Moore & Irwin Nazareth & Nicola Wiles & Louise Marston & Rachael Maree Hunter - 283-283 Correction to: Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study
by Caroline S. Clarke & Larisa Duffy & Glyn Lewis & Nick Freemantle & Simon Gilbody & Tony Kendrick & David Kessler & Michael King & Paul Lanham & Derelie Mangin & Michael Moore & Irwin Nazareth & Nicola Wiles & Louise Marston & Rachael Maree Hunter - 285-285 Correction to: The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations
by Siyuan Liu & Paul J. Veugelers & Chunhao Liu & Arto Ohinmaa
January 2022, Volume 20, Issue 1
- 5-8 Financial Incentives in the Path to Recovery from the COVID-19 Pandemic
by Afschin Gandjour - 9-11 Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers
by Jonathan Karnon & Andrew Partington & Hossein Afzali - 13-18 Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment
by James Lomas & Jessica Ochalek & Rita Faria - 19-33 Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review
by Margherita Neri & Patricia Cubi-Molla & Graham Cookson - 35-54 Quality of Health Economic Evaluations in Mainland China: A Comparison of Peer-Reviewed Articles in Chinese and in English
by Jiehua Cheng & Yu Zhang & Ailin Zhong & Miao Tian & Guanyang Zou & Xiaping Chen & Hongxing Yu & Fujian Song & Shangcheng Zhou - 55-65 Is There Broad-Based Support in High-Income Countries for COVID-19 Vaccine Donation? Evidence from Seven Countries
by Laurence S. J. Roope & Adrian Barnett & Paolo Candio & Mara Violato & Raymond Duch & Philip M. Clarke - 67-77 Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America
by Daniela Moye-Holz & S. Vogler - 79-89 Economic Evaluation of an Intervention Designed to Reduce Bullying in Australian Schools
by Amarzaya Jadambaa & Nicholas Graves & Donna Cross & Rosana Pacella & Hannah J. Thomas & James G. Scott & Qinglu Cheng & David Brain - 91-104 Costs and Cost-Effectiveness of User-Testing of Health Professionals’ Guidelines to Reduce the Frequency of Intravenous Medicines Administration Errors by Nurses in the United Kingdom: A Probabilistic Model Based on Voriconazole Administration
by Matthew D. Jones & Bryony Dean Franklin & D. K. Raynor & Howard Thom & Margaret C. Watson & Rebecca Kandiyali - 105-117 Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward
by Eleanor Bell & Margherita Neri & Lotte Steuten - 119-131 Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores
by Aurelie Meunier & Alexandra Soare & Helene Chevrou-Severac & Karl-Johan Myren & Tatsunori Murata & Louise Longworth - 133-143 Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis
by Andrea Marcellusi & Claudia Simonelli & Francesco S. Mennini & Loreta A. Kondili
November 2021, Volume 19, Issue 6
- 785-788 Towards a New Understanding of Unmet Medical Need
by Kyann Zhang & Gayathri Kumar & Chris Skedgel - 789-795 Methodological Note: Reporting Deterministic versus Probabilistic Results of Markov, Partitioned Survival and Other Non-Linear Models
by Edward C. F. Wilson - 797-810 How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, England
by Caroline S. Clarke & Cecilia Vindrola-Padros & Claire Levermore & Angus I. G. Ramsay & Georgia B. Black & Kathy Pritchard-Jones & John Hines & Gillian Smith & Axel Bex & Muntzer Mughal & David Shackley & Mariya Melnychuk & Steve Morris & Naomi J. Fulop & Rachael M. Hunter - 811-823 National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India
by Shankar Prinja & Yashika Chugh & Kavitha Rajsekar & V. R. Muraleedharan - 825-838 Systematic Literature Review of Guidelines on Budget Impact Analysis for Health Technology Assessment
by Yashika Chugh & Maria Francesco & Shankar Prinja - 839-855 Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta-analysis
by Leila Doshmangir & Edris Hasanpoor & Gerard Joseph Abou Jaoude & Behzad Eshtiagh & Hassan Haghparast-Bidgoli - 857-869 The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review
by Emily Leckenby & Dalia Dawoud & Jacoline Bouvy & Páll Jónsson - 871-883 COVID-19 Vaccine Demand and Financial Incentives
by Carlos E. Carpio & Ioana A. Coman & Oscar Sarasty & Manuel García - 885-903 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13
by Stephen Martin & James Lomas & Karl Claxton & Francesco Longo - 905-914 EQ-5D-5L Health-State Values for the Mexican Population
by Cristina Gutierrez-Delgado & Rosa-María Galindo-Suárez & Cesar Cruz-Santiago & Koonal Shah & Manny Papadimitropoulos & Yan Feng & Bernarda Zamora & Nancy Devlin - 915-927 Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe
by Luka Vončina & Tea Strbad & Jurij Fürst & Maria Dimitrova & Maria Kamusheva & Megi Vila & Ileana Mardare & Kristina Hristova & Andras Harsanyi & Dragana Atanasijević & Igor Banović & Ana Bobinac - 929-940 Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
by B. Muresan & C. Mamolo & J. C. Cappelleri & M. J. Postma & B. Heeg - 941-951 The Health and Productivity Burden of Depression in South Korea
by Ella Zomer & YongJoo Rhee & Danny Liew & Zanfina Ademi - 953-953 Correction to: Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta‑analysis
by Leila Doshmangir & Edris Hasanpoor & Gerard Joseph Abou Jaoude & Behzad Eshtiagh & Hassan Haghparast-Bidgoli
September 2021, Volume 19, Issue 5
- 625-634 Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies
by Jennifer G. Gaultney & Jacoline C. Bouvy & Richard H. Chapman & Alexander J. Upton & Stacey Kowal & Carsten Bokemeyer & Oriol Solà-Morales & Jürgen Wolf & Andrew H. Briggs - 635-644 Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
by Patricia Cubi-Molla & Martin Buxton & Nancy Devlin - 645-651 A Review of Web-Based Tools for Value-of-Information Analysis
by Haitham Tuffaha & Claire Rothery & Natalia Kunst & Chris Jackson & Mark Strong & Stephen Birch - 653-664 ‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions
by Rhiannon Tudor Edwards & Catherine Louise Lawrence - 665-672 The PLASMA System for Transurethral Resection of the Prostate: A NICE Medical Technologies Guidance Update
by Laura Knight & Susan Peirce & Rhys Morris - 673-697 A Systematic Review of the Costs Relating to Non-pharmaceutical Interventions Against Infectious Disease Outbreaks
by Janetta E. Skarp & Laura E. Downey & Julius W. E. Ohrnberger & Lucia Cilloni & Alexandra B. Hogan & Abagael L. Sykes & Susannah S. Wang & Hiral Anil Shah & Mimi Xiao & Katharina Hauck - 699-708 Using Constrained Optimization for the Allocation of COVID-19 Vaccines in the Philippines
by Christian Alvin H. Buhat & Destiny S. M. Lutero & Yancee H. Olave & Kemuel M. Quindala & Mary Grace P. Recreo & Dylan Antonio S. J. Talabis & Monica C. Torres & Jerrold M. Tubay & Jomar F. Rabajante - 709-719 How Much Money Should be Paid for a Patient to Isolate During the COVID-19 Outbreak? A Discrete Choice Experiment in Iran
by Enayatollah Homaie Rad & Mohammad Hajizadeh & Vahid Yazdi-Feyzabadi & Sajad Delavari & Zahra Mohtasham-Amiri - 721-733 The Impact of Financing Health Services on Income Inequality in an Unequal Society: The Case of South Africa
by John E. Ataguba - 735-745 Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
by Han Geul Byun & Minyoung Jang & Hyun Kyeong Yoo & James Potter & Taek Sang Kwon - 747-756 Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study
by Victoria K. Brennan & Georgina Jones & Stephen Radley & Simon Dixon - 757-767 Consumers' Preferences and Willingness to Pay for Personalised Nutrition
by Daniel Pérez-Troncoso & David M. Epstein & José A. Castañeda-García - 769-782 Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data
by Jeetendra Yadav & Geetha R. Menon & Denny John - 783-784 Comment on: “Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data”
by Nafis Faizi & Yasir Alvi
July 2021, Volume 19, Issue 4
- 453-461 Cost of Medicare for All: Review of the Estimates
by John A. Nyman - 463-472 Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines
by Chris Painter & Wanrudee Isaranuwatchai & Juthamas Prawjaeng & Hwee Lin Wee & Brandon Wen Bing Chua & Vinh Anh Huynh & Jing Lou & Fang Ting Goh & Nantasit Luangasanatip & Wirichada Pan-Ngum & Wang Yi & Hannah Clapham & Yot Teerawattananon - 473-486 Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations
by M. Cochrane & E. Mitchell & W. Hollingworth & E. Crawley & D. Trépel - 487-499 Economic Analyses of Pathogen-Reduction Technologies in Blood Transfusion: A Systematic Literature Review
by Patrick R. LaFontaine & Jing Yuan & Katherine M. Prioli & Priti Shah & Jay H. Herman & Laura T. Pizzi - 501-520 Costs of Illness of Spinal Muscular Atrophy: A Systematic Review
by Erik Landfeldt & Astrid Pechmann & Hugh J. McMillan & Hanns Lochmüller & Thomas Sejersen - 521-535 Preferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom
by James Buchanan & Laurence S. J. Roope & Liz Morrell & Koen B. Pouwels & Julie V. Robotham & Lucy Abel & Derrick W. Crook & Tim Peto & Christopher C. Butler & A. Sarah Walker & Sarah Wordsworth - 537-544 Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis
by George Dranitsaris & Carlo DeAngelis & Blake Pearson & Laura McDermott & Bernd Pohlmann-Eden - 545-555 Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
by Siin Kim & Sola Han & Hyungtae Kim & Hae Sun Suh - 557-577 The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil
by Wânia Cristina Silva & Brian Godman & Francisco Acúrcio & Mariângela Leal Cherchiglia & Antony Martin & Konrad Maruszczyk & Jans Bastos Izidoro & Marcos André Portella & Agner Pereira Lana & Orozimbo Henriques Campos Neto & Eli Iola Gurgel Andrade - 579-591 The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data
by Cathrine Elgaard Jensen & Sabrina Storgaard Sørensen & Claire Gudex & Morten Berg Jensen & Kjeld Møller Pedersen & Lars Holger Ehlers - 593-604 Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn’s Disease
by Tomas Mlcoch & Barbora Decker & Tomas Dolezal - 605-618 Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
by Jingyan Yang & Rongzhe Liu & Varun Ektare & Jennifer Stephens & Ahmed Shelbaya - 619-621 Comment on: “Willingness to Pay for a COVID-19 Vaccine”
by Philipp Sprengholz & Cornelia Betsch - 623-624 Authors’ Reply to Sprengholz and Betsch: “Willingness to Pay for a COVID-19 Vaccine”
by Leidy Y. García & Arcadio A. Cerda
May 2021, Volume 19, Issue 3
- 281-304 Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries
by Yitong Wang & Tingting Qiu & Junwen Zhou & Clément Francois & Mondher Toumi - 305-312 Copula Models for Addressing Sample Selection in the Evaluation of Public Health Programmes: An Application to the Leeds Let’s Get Active Study
by Paolo Candio & Andrew J. Hill & Stavros Poupakis & Anni-Maria Pulkki-Brännström & Chris Bojke & Manuel Gomes - 313-324 The Cost-Effectiveness of Pulmonary Rehabilitation for COPD in Different Settings: A Systematic Review
by Shengnan Liu & Qiheng Zhao & Wenshuo Li & Xuetong Zhao & Kun Li - 325-341 The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review
by Nicolas Iragorri & Claire Oliveira & Natalie Fitzgerald & Beverley Essue - 343-351 Willingness to Pay for a COVID-19 Vaccine
by Arcadio A. Cerda & Leidy Y. García - 353-370 Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme
by Shankar Prinja & Maninder Pal Singh & Kavitha Rajsekar & Oshima Sachin & Praveen Gedam & Anu Nagar & Balram Bhargava - 371-387 Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
by Pingyu Chen & Min Jin & Yang Cao & Hongchao Li - 389-401 What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches
by Anthony J. Hatswell & Ash Bullement & Michael Schlichting & Murtuza Bharmal - 403-414 Potential Unintended Consequences of National Infectious Disease Screening Strategies in Deceased Donor Kidney Transplantation: A Cost-Effectiveness Analysis
by Trevor A. Ellison & Samantha Clark & Jonathan C. Hong & Kevin D. Frick & Dorry L. Segev - 415-428 Prescription Drug Monitoring Programs and Opioid Prescriptions for Disability Conditions
by Orgul Ozturk & Yuan Hong & Suzanne McDermott & Margaret Turk - 429-437 Management of Chest Indrawing Pneumonia in Children Under Five Years at the Outpatient Health Facilities in Nigeria: An Economic Evaluation
by Charles E. Okafor - 439-450 Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies
by Sun-Hong Kwon & Hea-Sun Park & Young-Jin Na & Chul Park & Ju-Young Shin & Hye-Lin Kim - 451-451 Correction to: Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India’s National Publicly Financed Health Insurance Scheme
by Shankar Prinja & Maninder Pal Singh & Kavitha Rajsekar & Oshima Sachin & Praveen Gedam & Anu Nagar & Balram Bhargava
March 2021, Volume 19, Issue 2
- 141-144 The Vatican City State Internal Healthcare System Response to COVID-19 Pandemic: Prevention and Control Strategies
by Andrea Arcangeli & Massimo Ralli & Fabio De-Giorgio & Paolo Maurizio Soave & Lucia Ercoli - 145-153 Curos™ Disinfection Caps for the Prevention of Infection When Using Needleless Connectors: A NICE Medical Technologies Guidance
by Susan O’Connell & Megan Dale & Helen Morgan & Kimberley Carter & Grace Carolan-Rees - 155-162 Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review
by William V. Padula & Hui-Han Chen & Charles E. Phelps - 163-180 The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations
by Fei Yang & Meixia Liao & Pusheng Wang & Zheng Yang & Yongguang Liu - 181-190 How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany
by Afschin Gandjour - 191-202 French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30
by Virginie Nerich & Eva Maria Gamper & Richard Norman & Madeleine King & Bernhard Holzner & Rosalie Viney & Georg Kemmler - 203-215 Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD
by Kate M. Johnson & Mohsen Sadatsafavi & Amin Adibi & Larry Lynd & Mark Harrison & Hamid Tavakoli & Don D. Sin & Stirling Bryan - 217-229 Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
by Mujaheed Shaikh & Pietro Giudice & Dimitrios Kourouklis - 231-241 Budget Impact of Microbial Cell-Free DNA Testing Using the Karius® Test as an Alternative to Invasive Procedures in Immunocompromised Patients with Suspected Invasive Fungal Infections
by Ann T. MacIntyre & Alex Hirst & Radha Duttagupta & Desiree Hollemon & David K. Hong & Timothy A. Blauwkamp - 243-252 Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK
by Rucha Vadia & Tom Stargardt - 253-266 Identifying Community Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: A Discrete Choice Experiment
by Rakhee Raghunandan & Kirsten Howard & Carlo A. Marra & June Tordoff & Alesha Smith - 267-277 Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme
by Beena Joshi & Kusum V. Moray & Oshima Sachin & Himanshu Chaurasia & Shahina Begum - 279-279 Correction to: Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme
by Beena Joshi & Kusum V. Moray & Oshima Sachin & Himanshu Chaurasia & Shahina Begum
January 2021, Volume 19, Issue 1
- 5-8 Economic Theory and Medical Assistance in Dying
by Donald A. Redelmeier & Allan S. Detsky - 9-15 Using a Formal Strategy of Priority Setting to Mitigate Austerity Effects Through Gains in Value: The Role of Program Budgeting and Marginal Analysis (PBMA) in the Brazilian Public Healthcare System
by Brayan V. Seixas & Craig Mitton - 17-27 Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions
by Dina Jankovic & Laura Bojke & David Marshall & Pedro Saramago Goncalves & Rachel Churchill & Hollie Melton & Sally Brabyn & Lina Gega - 29-44 Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results
by Ru Han & Clément François & Mondher Toumi - 45-56 Elections have Consequences: Partisan Politics may be Literally Killing Us
by Alexander Maas & Liang Lu - 57-68 Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator
by Moritz Hadwiger & Fabian-Simon Frielitz & Nora Eisemann & Christian Elsner & Nikolaos Dagres & Gerhard Hindricks & Alexander Katalinic - 69-79 Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
by Shanshan Hu & Xun Deng & Yanjiao Ma & Zhilei Li & Yuhang Wang & Yong Wang - 81-96 Availability and Variability of Consumer Prices for Lumbar Discectomy Across US Hospitals in 2018
by Alexander J. Butler & Caroline J. Granger & Sebastian Rivera & Chester J. Donnally & Alexander Ghasem & Deborah Li & Michael Y. Wang - 97-109 Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer
by Julia Simoes Correa-Galendi & Maria Pilar Estevez Diz & Stephanie Stock & Dirk Müller - 111-121 Using Eye-Tracking Technology with Older People in Memory Clinics to Investigate the Impact of Mild Cognitive Impairment on Choices for EQ-5D-5L Health States Preferences
by Kaiying Wang & Chris Barr & Richard Norman & Stacey George & Craig Whitehead & Julie Ratcliffe - 123-132 Economic Evaluation of Senshio® (Ospemifene) for the Treatment of Vulvovaginal Atrophy in Scotland
by Amy Dymond & Hayden Holmes & Jessica McMaster & Joyce Craig & Heather Davies & Stuart Mealing & Rodolphe Perard - 133-140 Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland
by Amelia Smith & Stephen Doran & Maria Daly & Cormac Kennedy & Michael Barry
December 2020, Volume 18, Issue 6
- 743-746 Health Financing in Sub-Saharan Africa: From Analytical Frameworks to Empirical Evaluation
by Augustine Asante & Wilson S. K. Wasike & John E. Ataguba - 747-757 An Alternative Approach to Decomposing the Redistributive Effect of Health Financing Between and Within Groups Using the Gini Index: The Case of Out-of-Pocket Payments in Nigeria
by John E. Ataguba & Hyacinth E. Ichoku & Chijioke O. Nwosu & James Akazili - 759-766 Evaluating Equity in Health Financing Using Benefit Incidence Analysis: A Framework for Accounting for Quality of Care
by Augustine Asante & Nicola Man & Virginia Wiseman - 767-780 Analyzing the Financial Sustainability of User Fee Removal Policies: A Rapid First Assessment Methodology with a Practical Application for Burkina Faso
by Jacky Mathonnat & Martine Audibert & Salam Belem - 781-788 Estimating Catastrophic Health Expenditures from Household Surveys: Evidence from Living Standard Measurement Surveys (LSMS)-Integrated Surveys on Agriculture (ISA) from Sub-Saharan Africa
by Sarah Ssewanyana & Ibrahim Kasirye - 789-799 An Assessment of Domestic Financing for Reproductive, Maternal, Neonatal and Child Health in Sub-Saharan Africa: Potential Gains and Fiscal Space
by Chris Atim & Eric Arthur & Daniel Malik Achala & Jacob Novignon - 801-810 Performance-Based Financing, Basic Packages of Health Services and User-Fee Exemption Mechanisms: An Analysis of Health-Financing Policy Integration in Three Fragile and Conflict-Affected Settings
by Eelco Jacobs & Maria Paola Bertone & Jurrien Toonen & Ngozi Akwataghibe & Sophie Witter - 811-823 Payment Arrangements for Private Healthcare Purchasing Under Publicly Funded Systems in Low- and Middle-Income Countries: Issues and Implications
by Ayako Honda & Amarech Obse - 825-840 Health Insurance in Sub-Saharan Africa: A Scoping Review of the Methods Used to Evaluate its Impact
by Stéphanie Degroote & Valery Ridde & Manuela Allegri
October 2020, Volume 18, Issue 5
- 597-599 The Inclusion of Comparative Environmental Impact in Health Technology Assessment: Practical Barriers and Unintended Consequences
by Brita A. K. Pekarsky - 601-604 Modeling Medicaid and Medicare Savings from Reduced Poverty and Disability to Promote Investment in Mental Health and Substance Use Interventions in the USA
by Nathaniel Z. Counts & Paul Gionfriddo & Richard H. Chapman - 605-623 Health Promoting Schools: An Update
by Albert Lee & Amelia Lo & Queenie Li & Vera Keung & Amy Kwong - 625-639 A Systematic Review of the Association Between Hospital Cost/price and the Quality of Care
by Sara Jamalabadi & Vera Winter & Jonas Schreyögg - 641-654 Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review
by Bernard O. Okeah & Colin H. Ridyard - 655-667 Effects of Monetary Incentives in Physician Groups: A Systematic Review of Reviews
by Ann-Kathrin Heider & Harald Mang - 669-677 The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis
by Jakub P. Hlávka & Soeren Mattke & Asa Wilks - 679-687 Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases
by Anh Dam Tran & Gerald Fogarty & Anna K. Nowak & Vakaramoko Diaby & Angela Hong & Caroline Watts & Rachael L. Morton - 689-698 Preferences for Weight Loss Treatment Amongst Treatment-Seeking Patients with Severe Obesity: A Discrete Choice Experiment
by Michelle Queally & Edel Doherty & Francis Finucane & Ciaran O’Neill - 699-711 Estimating the Unit Costs of Healthcare Service Delivery in India: Addressing Information Gaps for Price Setting and Health Technology Assessment
by Pankaj Bahuguna & Lorna Guinness & Sameer Sharma & Akashdeep Singh Chauhan & Laura Downey & Shankar Prinja - 713-726 Implementing Lifestyle Change Interventions to Prevent Type 2 Diabetes in US Medicaid Programs: Cost Effectiveness, and Cost, Health, and Health Equity Impact
by Michael Laxy & Ping Zhang & Boon Peng Ng & Hui Shao & Mohammed K. Ali & Ann Albright & Edward W. Gregg - 727-737 Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy
by Kim Edmunds & Penny Reeves & Paul Scuffham & Daniel A. Galvão & Robert U. Newton & Mark Jones & Nigel Spry & Dennis R. Taaffe & David Joseph & Suzanne K. Chambers & Haitham Tuffaha - 739-741 Comment on: “The Italian NHS: What Lessons to Draw from COVID-19?”
by Davide Golinelli & Andrea Bucci & Kadjo Yves Cedric Adja & Fabrizio Toscano
August 2020, Volume 18, Issue 4
- 461-462 The Potential Role of Constrained Optimization Methods in Healthcare Decision Making
by William H. Crown - 463-466 The Italian NHS: What Lessons to Draw from COVID-19?
by Livio Garattini & Michele Zanetti & Nicholas Freemantle - 467-475 Should Health Economic Evaluations Undertaken from a Societal Perspective Include Net Government Spending Multiplier Effects?
by Jonathan Karnon & Brita Pekarsky - 477-489 Do Research Groups Align on an Intervention’s Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders
by Matthew Sussman & Jeffrey C. Yu & Joseph Menzin - 491-508 Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review
by Elsa Bouée-Benhamiche & Philippe Jean Bousquet & Salah Ghabri - 509-517 The Efficacy of Lockdown Against COVID-19: A Cross-Country Panel Analysis
by Vincenzo Alfano & Salvatore Ercolano - 519-531 Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project
by Baudouin Standaert & Ilse Van Vlaenderen & Laure-Anne Van Bellinghen & Sandra Talbird & Katherine Hicks & Justin Carrico & Philip O. Buck - 533-545 Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA
by Mustafa Oguz & Tereza Lanitis & Xiaoyan Li & Gail Wygant & Daniel E. Singer & Keith Friend & Patrick Hlavacek & Andreas Nikolaou & Soeren Mattke - 547-556 Health State Values of Deaf British Sign Language (BSL) Users in the UK: An Application of the BSL Version of the EQ-5D-5L
by Gemma E. Shields & Katherine D. Rogers & Alys Young & Sofia Dedotsi & Linda M. Davies - 557-566 Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea
by Hye-Jae Lee & Euna Han & Hyero Kim - 567-578 Cost–Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model Simulation
by Mathias Baumann & Tom Stargardt & Simon Frey - 579-587 Estimating the Productivity Burden of Pediatric Pneumococcal Disease in Thailand
by Thanpisit Ounsirithupsakul & Piyameth Dilokthornsakul & Khachen Kongpakwattana & Zanfina Ademi & Danny Liew & Nathorn Chaiyakunapruk - 589-596 What Matters to Potential Patients in Chemotherapy Service Delivery? A Discrete Choice Experiment
by Richard Norman & Matthew Anstey & Arman Hasani & Ian Li & Suzanne Robinson
June 2020, Volume 18, Issue 3
- 325-328 COVID-19 Pandemic, a War to be Won: Understanding its Economic Implications for Africa
by John E. Ataguba - 329-331 A Simple Decision Analysis of a Mandatory Lockdown Response to the COVID-19 Pandemic
by Jonathan Karnon - 333-334 Why Only Test Symptomatic Patients? Consider Random Screening for COVID-19
by William V. Padula - 335-337 The Case for a Temporary COVID-19 Income Tax Levy Now, During the Crisis
by Jonathan Karnon - 339-343 Impact of a Global Pandemic on Health Technology Assessment
by Paula K. Lorgelly & Amanda Adler - 345-350 Using Insights from Behavioral Economics to Mitigate the Spread of COVID-19
by Moslem Soofi & Farid Najafi & Behzad Karami-Matin - 351-356 The Relevant Perspective of Economic Evaluations Informing Local Decision Makers: An Exploration in Weight Loss Services
by Sebastian Hinde & Louise Horsfield & Laura Bojke & Gerry Richardson - 357-362 Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition
by Rosella Levaggi & Paolo Pertile - 363-373 iFuse Implant System for Treating Chronic Sacroiliac Joint Pain: A NICE Medical Technology Guidance
by Megan Dale & James Evans & Kimberley Carter & Susan O’Connell & Helen Morgan & Grace Carolan-Rees - 375-392 Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists
by Chiranjeev Sanyal & Don Husereau - 393-411 Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India
by Pankaj Bahuguna & Shankar Prinja & Chandrakant Lahariya & Radha Krishan Dhiman & Madhumita Prem Kumar & Vineeta Sharma & Arun Kumar Aggarwal & Rajesh Bhaskar & Hilde Graeve & Henk Bekedam - 413-432 Promoting HIV Testing by Men: A Discrete Choice Experiment to Elicit Preferences and Predict Uptake of Community-based Testing in Uganda
by Elisabeth M. Schaffer & Juan Marcos Gonzalez & Stephanie B. Wheeler & Dalsone Kwarisiima & Gabriel Chamie & Harsha Thirumurthy - 433-442 Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler
by Gustaf Ortsäter & Fredrik Borgström & Mike Baldwin & Carolin Miltenburger - 443-451 The Impact of Physicians’ Working Hours on Inappropriate Use of Outpatient Medicine in a Tertiary Hospital in China
by Xiaodong Guan & Bingyu Ni & Jingyuan Zhang & Chunxia Man & Zheng Cai & Wenshuang Meng & Luwen Shi & Dennis Ross-Degnan - 453-454 Comment on: ‘Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition’
by Livio Garattini & Nick Freemantle - 455-456 Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”
by Rosella Levaggi & Paolo Pertile - 457-458 Comment on: “A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance”
by J. P. Hays - 459-460 Authors’ Reply to Hays: “A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance”
by David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins
April 2020, Volume 18, Issue 2
- 143-145 Economics of Mental Health: Providing a Platform for Efficient Mental Health Policy
by Christopher M. Doran & Irina Kinchin - 147-153 Mental health: A Particular Challenge Confronting Policy Makers and Economists
by Peter Zweifel - 155-175 Universal Mental Health Interventions for Children and Adolescents: A Systematic Review of Health Economic Evaluations
by Masja Schmidt & Amber Werbrouck & Nick Verhaeghe & Koen Putman & Steven Simoens & Lieven Annemans - 177-188 Healthcare Costs for People with Serious Mental Illness in England: An Analysis of Costs Across Primary Care, Hospital Care, and Specialist Mental Healthcare
by Jemimah Ride & Panagiotis Kasteridis & Nils Gutacker & Maria Jose Aragon Aragon & Rowena Jacobs - 189-201 Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada
by Michael Lebenbaum & Joyce Cheng & Claire Oliveira & Paul Kurdyak & Juveria Zaheer & Rebecca Hancock-Howard & Peter C. Coyte - 203-221 The Evolution of Mental Health in the Context of Transitory Economic Changes
by Alexandrina Stoyanova & Jaime Pinilla - 223-235 Socioeconomic Disparities in Unmet Need for Student Mental Health Services in Higher Education
by John Cullinan & Sharon Walsh & Darragh Flannery